THE BIOLOGY OF HUMAN PROSTATE CANCER METASTASIS

人类前列腺癌转移的生物学

基本信息

  • 批准号:
    6563949
  • 负责人:
  • 金额:
    $ 29.18万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2002
  • 资助国家:
    美国
  • 起止时间:
    2002-01-24 至 2002-12-31
  • 项目状态:
    已结题

项目摘要

Background: The major cause of death from prostate cancer is metastases that are resistant to conventional therapies such as androgen ablation and cytotoxic chemotherapy. The design of effective new therapies against human prostate cancer bone metastasis requires a better understanding of the process at the systemic, cellular, and molecular levels. The outcome of metastasis depends on multiple continuous interactions between unique subpopulations of tumor cells and specific host factors, including the organ microenvironment, as exemplified by angiogenesis. Hypotheses and Specific Aims: These data suggest the hypothesis that the progressive growth and metastasis of prostate cancer are dependent on the induction of organ-specific angiogenesis associated with an imbalance between the pro-angiogenic molecules, such as interleukin (IL)-8 and ant- angiogenic molecules, such as interferon (IFN)-beta. Restoration of the balance, therefore, should inhibit angiogenesis and lead to tumor regression. To test this hypothesis, we shall use a nude mouse orthotopic model to select non-metastatic and metastatic cells from different human prostate cancers and to isolate and culture endothelial cells from different organs (bone, lung, and skin). We shall determine the metastatic genotypes and phenotypes of the variant cells and determine the mechanisms that regulate bone-specific angiogenesis. We shall determine the role of IL-8 in the progressive growth and metastasis of human prostate cancer and whether shall determine the role of IL-8 in the progressive growth and metastasis of human prostate cancer and whether the organ microenvironment regulates expression of IL-8. Recent data showed that neoplastic angiogenesis is associated with a decrease in tissue levels of IFN (alpha and beta), so we shall therefore determine whether chronic systemic administration of IFN inhibits angiogenesis of primary prostate cancer and bone metastases and whether the combination of IFN and chemotherapy can eradicate prostate cancer metastases. Finally, in preparation for clinical trials using low-dose IFN, we shall determine whether the expression levels of metastasis/angiogenesis-regulating genes in the prostate cancers of individual patients validate the experimental data and can serve as a surrogate marker for anti-angiogenic therapy. Significance: Understanding the process of prostate cancer angiogenesis and bone metastasis on the systemic, cellular, and molecular levels will be invaluable in designing new effective therapy.
工作背景:前列腺癌死亡的主要原因是对常规治疗如雄激素消融和细胞毒性化疗具有抗性的转移。针对人前列腺癌骨转移的有效新疗法的设计需要在系统、细胞和分子水平上更好地理解该过程。转移的结果取决于肿瘤细胞的独特亚群和特定宿主因子之间的多种连续相互作用,包括器官微环境,如血管生成所例示的。假设和具体目标:这些数据表明了这样的假设,即前列腺癌的进行性生长和转移依赖于与促血管生成分子如白介素(IL)-8和抗血管生成分子如干扰素(IFN)-β之间的不平衡相关的器官特异性血管生成的诱导。因此,平衡的恢复应该抑制血管生成并导致肿瘤消退。为了验证这一假设,我们将使用裸鼠原位模型来选择来自不同人前列腺癌的非转移性和转移性细胞,并分离和培养来自不同器官(骨、肺和皮肤)的内皮细胞。我们将确定变异细胞的转移基因型和表型,并确定调节骨特异性血管生成的机制。我们将确定IL-8在人前列腺癌进行性生长和转移中的作用,以及是否将确定IL-8在人前列腺癌进行性生长和转移中的作用,以及器官微环境是否调节IL-8的表达。最近的数据表明,肿瘤血管生成与IFN(α和β)的组织水平的降低有关,因此,我们将确定长期全身性给予IFN是否抑制原发性前列腺癌和骨转移的血管生成,以及IFN和化疗的组合是否可以根除前列腺癌转移。最后,在使用低剂量IFN的临床试验的准备中,我们将确定个体患者的前列腺癌中的转移/血管生成调节基因的表达水平是否验证了实验数据,并且可以作为抗血管生成治疗的替代标志物。重要性:从系统、细胞和分子水平上了解前列腺癌血管生成和骨转移的过程对于设计新的有效治疗方法将是非常宝贵的。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ISAIAH J FIDLER其他文献

ISAIAH J FIDLER的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ISAIAH J FIDLER', 18)}}的其他基金

Program Leaders
项目负责人
  • 批准号:
    7695924
  • 财政年份:
    2008
  • 资助金额:
    $ 29.18万
  • 项目类别:
CAREER DEVELOPMENT PROGRAM
职业发展计划
  • 批准号:
    6563957
  • 财政年份:
    2002
  • 资助金额:
    $ 29.18万
  • 项目类别:
CORE--CENTRALIZED HISTOPATHOLOGY LABORATORY
核心——集中组织病理学实验室
  • 批准号:
    6481852
  • 财政年份:
    2001
  • 资助金额:
    $ 29.18万
  • 项目类别:
Antiangiogenesis therapy of human ovarian cancer
人卵巢癌的抗血管生成治疗
  • 批准号:
    6347389
  • 财政年份:
    2000
  • 资助金额:
    $ 29.18万
  • 项目类别:
CORE--CENTRALIZED HISTOPATHOLOGY LABORATORY
核心——集中组织病理学实验室
  • 批准号:
    6347264
  • 财政年份:
    2000
  • 资助金额:
    $ 29.18万
  • 项目类别:
CORE--CENTRALIZED HISTOPATHOLOGY LABORATORY
核心——集中组织病理学实验室
  • 批准号:
    6334915
  • 财政年份:
    2000
  • 资助金额:
    $ 29.18万
  • 项目类别:
CORE--CENTRALIZED HISTOPATHOLOGY LABORATORY
核心——集中组织病理学实验室
  • 批准号:
    6352697
  • 财政年份:
    2000
  • 资助金额:
    $ 29.18万
  • 项目类别:
CORE--CENTRALIZED HISTOPATHOLOGY LABORATORY
核心——集中组织病理学实验室
  • 批准号:
    6314530
  • 财政年份:
    1999
  • 资助金额:
    $ 29.18万
  • 项目类别:
Antiangiogenesis therapy of human ovarian cancer
人卵巢癌的抗血管生成治疗
  • 批准号:
    6228662
  • 财政年份:
    1999
  • 资助金额:
    $ 29.18万
  • 项目类别:
CORE--CENTRALIZED HISTOPATHOLOGY LABORATORY
核心——集中组织病理学实验室
  • 批准号:
    6217259
  • 财政年份:
    1999
  • 资助金额:
    $ 29.18万
  • 项目类别:

相似海外基金

Development of oncolytic virus targeting tumor angiogenesis factor
靶向肿瘤血管生成因子的溶瘤病毒的研制
  • 批准号:
    20K09900
  • 财政年份:
    2020
  • 资助金额:
    $ 29.18万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
A pathophysiological significance of a novel angiogenesis factor in diabetic kidney disease and chronic kidney disease
新型血管生成因子在糖尿病肾病和慢性肾病中的病理生理学意义
  • 批准号:
    19K08730
  • 财政年份:
    2019
  • 资助金额:
    $ 29.18万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Identification and functional analysis of target microRNAs of angiogenesis factor regulating endochondral ossification
血管生成因子调节软骨内骨化的靶标microRNA的鉴定及功能分析
  • 批准号:
    25713064
  • 财政年份:
    2013
  • 资助金额:
    $ 29.18万
  • 项目类别:
    Grant-in-Aid for Young Scientists (A)
Investigation of mechanism of angiogenesis factor, angiogenin, as a molecular target against cancer-induced bone destruction
研究血管生成因子血管生成素作为对抗癌症引起的骨破坏的分子靶标的机制
  • 批准号:
    20390516
  • 财政年份:
    2008
  • 资助金额:
    $ 29.18万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Search of natural compound activating endogenous anti-angiogenesis factor as an anti-cancer agent.
寻找激活内源性抗血管生成因子的天然化合物作为抗癌剂。
  • 批准号:
    20510209
  • 财政年份:
    2008
  • 资助金额:
    $ 29.18万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Anti-angiogenesis therapy by transplantation of cells expressing anti-angiogenesis factor established by gene transductions
通过移植表达通过基因转导建立的抗血管生成因子的细胞进行抗血管生成治疗
  • 批准号:
    19390344
  • 财政年份:
    2007
  • 资助金额:
    $ 29.18万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Development of inhibitors for a angiogenesis factor CTGF and its application for angiogenetic diseases
血管生成因子CTGF抑制剂的研制及其在血管生成疾病中的应用
  • 批准号:
    10557165
  • 财政年份:
    1998
  • 资助金额:
    $ 29.18万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
The endogenous growth and angiogenesis factor in the placenta and the placental bed.
胎盘和胎盘床的内源性生长和血管生成因子。
  • 批准号:
    62570747
  • 财政年份:
    1987
  • 资助金额:
    $ 29.18万
  • 项目类别:
    Grant-in-Aid for General Scientific Research (C)
CELL BIOLOGY OF AN ANGIOGENESIS FACTOR
血管生成因子的细胞生物学
  • 批准号:
    3033035
  • 财政年份:
    1987
  • 资助金额:
    $ 29.18万
  • 项目类别:
Investigation of angiogenesis factor. - Basic research for a treatment of brain ischemic diseases including moyamoya disease. -
血管生成因子的研究。
  • 批准号:
    61570688
  • 财政年份:
    1986
  • 资助金额:
    $ 29.18万
  • 项目类别:
    Grant-in-Aid for General Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了